Deutsche Bank AG Boosts Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Deutsche Bank AG lifted its position in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 24.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 36,653 shares of the company’s stock after purchasing an additional 7,128 shares during the quarter. Deutsche Bank AG’s holdings in Tango Therapeutics were worth $113,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Tango Therapeutics during the fourth quarter valued at about $33,000. Ameriprise Financial Inc. acquired a new stake in Tango Therapeutics during the 4th quarter worth approximately $35,000. Teacher Retirement System of Texas grew its stake in shares of Tango Therapeutics by 35.8% in the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company’s stock worth $45,000 after acquiring an additional 3,831 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Tango Therapeutics in the fourth quarter valued at $45,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Tango Therapeutics by 29.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company’s stock valued at $65,000 after purchasing an additional 4,813 shares during the period. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Tango Therapeutics in a research report on Monday, April 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Tango Therapeutics currently has a consensus rating of “Buy” and an average target price of $12.20.

Tango Therapeutics Trading Up 27.6%

Tango Therapeutics stock opened at $3.24 on Wednesday. The company has a fifty day simple moving average of $1.55 and a 200-day simple moving average of $2.38. The stock has a market cap of $351.20 million, a P/E ratio of -2.75 and a beta of 1.02. Tango Therapeutics, Inc. has a 12-month low of $1.03 and a 12-month high of $12.02.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.02). The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $6.73 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. As a group, sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.